Glutamate as a therapeutic target in psychiatric disorders.
about
A review of anti-inflammatory agents for symptoms of schizophreniaA novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expressionGroup II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortexTo use or not to use: an update on licit and illicit ketamine useNeurotransmitter transporters and their impact on the development of psychopharmacologyTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsBrain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter SystemsMolecular Pathogenesis of Anti-NMDAR EncephalitisAntidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradationPrenatal stress and peripubertal stimulation of the endocannabinoid system differentially regulate emotional responses and brain metabolism in miceProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaN-methyl-D-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder.Identification of developmentally regulated PCP-responsive non-coding RNA, prt6, in the rat thalamusThe neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity.Inhibition of D-serine accumulation in the Xenopus oocyte by expression of the rat ortholog of human 3'-phosphoadenosine 5'-phosphosulfate transporter gene isolated from the neocortex as D-serine modulator-1Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implicationsAn update of the classical and novel methods used for measuring fast neurotransmitters during normal and brain altered functionBehavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment--role of brain kynurenic acid.Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidatesComprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes.Disruption of Arp2/3 results in asymmetric structural plasticity of dendritic spines and progressive synaptic and behavioral abnormalitiesMouse pharmacological models of cognitive disruption relevant to schizophrenia.Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control.Impacts of forebrain neuronal glycine transporter 1 disruption in the senescent brain: evidence for age-dependent phenotypes in Pavlovian learning.N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice.Prepulse inhibition and genetic mouse models of schizophrenia.PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptorsNMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.The mismatch negativity: a review of underlying mechanisms.Molecular targets for treating cognitive dysfunction in schizophrenia.Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Neurobiological background of negative symptoms.NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique.Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortexThe site specific demethylation in the 5'-regulatory area of NMDA receptor 2B subunit gene associated with CIE-induced up-regulation of transcription.Epigenetic Activation of ASCT2 in the Hippocampus Contributes to Depression-Like Behavior by Regulating D-Serine in Mice.
P2860
Q22241827-F8FCD367-F02A-4115-8F68-9F1E65F9AFF8Q24607731-5B5E55C0-2DA7-4964-9E5D-491FB0F1D50EQ24612550-0C555E4B-B83B-4F21-90B1-5B8CCB1EA3DEQ24634006-48995D01-3E25-4113-993D-AC7409473037Q24670273-DEBA8D6B-0454-42B0-92DC-A024BCD1F001Q26752602-105EE159-DDA4-44F0-A779-79F736FF8793Q26786247-D0057966-661F-4113-B358-14957483EC25Q26801883-E566FB8D-FDC2-430D-805D-B373803436AEQ27319514-34538792-6288-4280-B9CC-C8A916365C83Q27330142-BDF1780E-8B87-4C50-96E9-ED969BC95A3DQ28240120-06D66C3E-40AE-490C-929F-6530D66C9ACFQ28285432-3804BABC-E37F-4A48-ACD7-13EF779137A8Q28539216-321597E9-2DE4-42F0-837E-B8E16368630AQ28568657-7001A9CE-CF07-4B54-A50E-097EA8E31A13Q28576131-77E91F20-F450-41FE-A6E0-8FDDC746FF4FQ30370326-283A80A6-9D6F-42CF-8A6C-D928615BB511Q30376372-49C89DB7-164C-4C64-AB6E-B347CDDE2DB8Q30410156-72E0B487-B3AA-4CDC-9928-71803A9FE450Q30419650-D0632EEE-230D-4CD0-9AB1-0F764B30285CQ30423149-082C8759-F171-4D10-8A1B-702255C93472Q30438410-0953D88F-2CBA-44B2-AAF5-66F94145A9ADQ30448529-FB6DD614-5C72-4C55-81E1-71A01CE7D5E4Q30457807-FA68E515-4C24-44BC-BB36-8899C2D47F39Q30459497-76339AD0-28FE-488E-81E2-D6ACEF0AAAD6Q30463374-74A13DEB-EA72-405F-B5D7-0E65771D5C65Q30472470-56F3DEE5-4CA8-4902-B412-0229F99BA3D8Q30474021-389753C2-7FF3-4A5F-AE86-752173315DAFQ30476572-B5E090C6-589B-41B3-9F50-4CC74ACF7281Q30478270-73829096-C710-404F-BEEF-C559329B7199Q30482703-C970B7DD-BDD8-4686-B692-999D63647957Q30484119-61FBC933-27F4-4038-9CD4-5A9080389E60Q30490060-6609FC4C-FA7A-429B-9A03-3256B46B8C96Q30491310-8465333D-C5D1-40A5-85BB-CE97C06F8D1EQ30564474-8C1E1BF8-7A82-4C92-AE8A-84330214A82AQ30685335-5A54C53B-236F-4D01-82F2-269A3C8AE841Q30913824-33AE50C6-58F5-4BE3-87A8-9D9AE543A998Q33374928-0D74198F-A010-4A42-BB56-C6FD2E245081Q33444363-09AADC77-872F-4307-9E0B-4B7FD45B443BQ33526324-0673DF35-BB7C-430F-B5F1-8341CD2D9503Q33650476-73BEE6CF-6BFF-406D-B38C-67EED3EF239C
P2860
Glutamate as a therapeutic target in psychiatric disorders.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Glutamate as a therapeutic target in psychiatric disorders.
@ast
Glutamate as a therapeutic target in psychiatric disorders.
@en
type
label
Glutamate as a therapeutic target in psychiatric disorders.
@ast
Glutamate as a therapeutic target in psychiatric disorders.
@en
prefLabel
Glutamate as a therapeutic target in psychiatric disorders.
@ast
Glutamate as a therapeutic target in psychiatric disorders.
@en
P356
P1433
P1476
Glutamate as a therapeutic target in psychiatric disorders.
@en
P2093
P2888
P304
984-97, 979
P356
10.1038/SJ.MP.4001551
P407
P577
2004-11-01T00:00:00Z